E2F-1 as an anticancer drug target

Main Article Content

Joseph R. Bertino (1*), Debabrata Banerjee (2)

1 Departments of Medicine and Pharmacology, Cancer Institute of New Jersey, Robert Wood Johnson Medical School, University of Medicine and Dentistry, New Brunswick, United States.
2 Departments of Medicine and Pharmacology, Cancer Institute of New Jersey, Robert Wood Johnson Medical School, University of Medicine and Dentistry, New Brunswick, United States.
(*) Corresponding Author:
Joseph R. Bertino
bertinoj@umdnj.edu

Abstract

Mounting evidence indicates that the E2F transcription factors play an essential role in all aspects of cellular functions. Many human malignancies have been shown to overexpress one or more of the ‘‘activating’’ E2Fs. In some circumstances, down regulation as well as overexpression of E2F-1, leads to inhibition of cell growth. The emphasis in this review is placed on new data implicating microRNAs in the regulation of E2F activity and the efforts thus far to target this activity in order to cause tumor regression.

Downloads month by month

Downloads

Download data is not yet available.

Article Details

How to Cite
Bertino, J. R., & Banerjee, D. (2011). E2F-1 as an anticancer drug target. Oncology Reviews, 3(4), 207-214. https://doi.org/10.4081/oncol.2009.207